From T cells to NK cells and macrophages: progress and challenges in CAR-based therapies and the involved gene delivery systems.
2/5 보강
OpenAlex 토픽 ·
Immune Cell Function and Interaction
CAR-T cell therapy research
Phagocytosis and Immune Regulation
Chimeric antigen receptor (CAR)-based therapies have transformed the treatment of hematological malignancies, with CAR-T cell therapies establishing themselves as effective clinical options.
APA
Margarida C. Guerreiro, Inês S. Pinto, et al. (2026). From T cells to NK cells and macrophages: progress and challenges in CAR-based therapies and the involved gene delivery systems.. International journal of pharmaceutics, 696, 126848. https://doi.org/10.1016/j.ijpharm.2026.126848
MLA
Margarida C. Guerreiro, et al.. "From T cells to NK cells and macrophages: progress and challenges in CAR-based therapies and the involved gene delivery systems.." International journal of pharmaceutics, vol. 696, 2026, pp. 126848.
PMID
41936892 ↗
Abstract 한글 요약
Chimeric antigen receptor (CAR)-based therapies have transformed the treatment of hematological malignancies, with CAR-T cell therapies establishing themselves as effective clinical options. Building on this success, recent research has expanded CAR engineering to natural killer (CAR-NK) cells and macrophages (CAR-M), aiming to address key limitations such as manufacturing complexity, safety concerns, and suboptimal efficacy against solid tumors. Advances in non-viral gene delivery systems have further progressed the field, providing alternatives to traditional viral vectors by enabling efficient, scalable, and less toxic CAR gene transfer. This review summarizes the evolution and latest developments in CAR-T, CAR-NK, and CAR-M therapies, with a focus on innovative non-viral delivery platforms. We highlight current clinical achievements, ongoing challenges, and the convergence of cell engineering and delivery approaches that are broadening the therapeutic potential of CAR technology. Continued progress in these areas can make personalized, targeted cancer immunotherapies more accessible, versatile, and beneficial for a wider patient population.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- A Phase I Study of Hydroxychloroquine and Suba-Itraconazole in Men with Biochemical Relapse of Prostate Cancer (HITMAN-PC): Dose Escalation Results.
- Self-management of male urinary symptoms: qualitative findings from a primary care trial.
- Clinical and Liquid Biomarkers of 20-Year Prostate Cancer Risk in Men Aged 45 to 70 Years.
- Diagnostic accuracy of Ga-PSMA PET/CT versus multiparametric MRI for preoperative pelvic invasion in the patients with prostate cancer.
- Association of patient health education with the postoperative health related quality of life in low- intermediate recurrence risk differentiated thyroid cancer patients.
- Early local immune activation following intra-operative radiotherapy in human breast tissue.